<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33297428</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Recombinant Enterovirus 71 Viral Protein 1 Fused to a Truncated Newcastle Disease Virus NP (NPt) Carrier Protein.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">742</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines8040742</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is the major causative agent in hand, foot, and mouth disease (HFMD), and it mainly infects children worldwide. Despite the risk, there is no effective vaccine available for this disease. Hence, a recombinant protein construct of truncated nucleocapsid protein viral protein 1 (NPt-VP1<sub>198-297</sub>), which is capable of inducing neutralizing antibody against EV71, was evaluated in a mouse model. Truncated nucleocapsid protein Newcastle disease virus that was used as immunological carrier fused to VP1 of EV71 as antigen. The recombinant plasmid carrying corresponding genes was constructed by recombinant DNA technology and the corresponding protein was produced in <i>Escherichia coli</i> expression system. The recombinant NPt-VP1<sub>198-297</sub> protein had elicited neutralizing antibodies against EV71 with the titer of 1:16, and this result is higher than the titer that is elicited by VP1 protein alone (1:8). It was shown that NPt containing immunogenic epitope(s) of VP1 was capable of inducing a greater functional immune response when compared to full-length VP1 protein alone. It was capable to carry larger polypeptide compared to full-length NP protein. The current study also proved that NPt-VP1<sub>198-297</sub> protein can be abundantly produced in recombinant protein form by <i>E. coli</i> expression system. The findings from this study support the importance of neutralizing antibodies in EV71 infection and highlight the potential of the recombinant NPt-VP1<sub>198-297</sub> protein as EV71 vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Suhaili</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3384-1397</Identifier><AffiliationInfo><Affiliation>Department of Animal Science and Fishery, Universiti Putra Malaysia, Bintulu Sarawak Campus, Bintulu 97008, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd-Aziz</LastName><ForeName>Noraini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Virus and Vaccine Research (CVVR), School of Science and Technology, Sunway University, Subang Jaya 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saw</LastName><ForeName>Wuan-Ting</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Sien-Yei</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusoff</LastName><ForeName>Khatijah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafee</LastName><ForeName>Norazizah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>9358000</GrantID><Agency>Institute of Pharmaceutical Malaysia (IPHARM), Ministry of Science and Technology (MOSTI)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">nucleocapsid protein</Keyword><Keyword MajorTopicYN="N">recombinant vaccine construct</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>10</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33297428</ArticleId><ArticleId IdType="pmc">PMC7762238</ArticleId><ArticleId IdType="doi">10.3390/vaccines8040742</ArticleId><ArticleId IdType="pii">vaccines8040742</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, Foot, and Mouth Disease in China, 2008&#x2013;2012: An Epidemiological Study. Lancet Infect. Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, Epidemiology, Pathogenesis, and Control of Enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J. Infect. Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambyah P.A., Oon J., Asli R., Kristanto W., Hwa S.H., Vang F., Karwal L., Fuchs J., Santangelo J.D., Gordon G.S., et al. An Inactivated Enterovirus 71 Vaccine Is Safe and Immunogenic in Healthy Adults: A Phase I, Double Blind, Randomized, Placebo-Controlled, Study of Two Dosages. Vaccine. 2019;37:4344&#x2013;4353. doi: 10.1016/j.vaccine.2019.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.06.023</ArticleId><ArticleId IdType="pubmed">31230881</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Mao F., Pang Z., Yi Y., Qiu F., Tian R., Meng Q., Jia Z., Bi S. Protective Effect of Enterovirus-71 (EV71) Virus-like Particle Vaccine against Lethal EV71 Infection in a Neonatal Mouse Model. Mol. Med. Rep. 2015;12:2473&#x2013;2480. doi: 10.3892/mmr.2015.3680.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2015.3680</ArticleId><ArticleId IdType="pmc">PMC4464482</ArticleId><ArticleId IdType="pubmed">25936344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease. J. Virol. 2010;84:661&#x2013;665. doi: 10.1128/JVI.00999-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., Hu Y.C. Immunization with Virus-like Particles of Enterovirus 71 Elicits Potent Immune Responses and Protects Mice against Lethal Challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against Lethal Enterovirus 71 Infection in Newborn Mice by Passive Immunization with Subunit VP1 Vaccines and Inactivated Virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Kolpe A.B., Kiener T.K., Chow V.T.K., Kwang J. Display of VP1 on the Surface of Baculovirus and Its Immunogenicity against Heterologous Human Enterovirus 71 Strains in Mice. PLoS ONE. 2011;6:e21757. doi: 10.1371/journal.pone.0021757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021757</ArticleId><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.F., Chang M.H., Chiang B.L., Jeng S.T. Oral Immunization of Mice Using Transgenic Tomato Fruit Expressing VP1 Protein from Enterovirus 71. Vaccine. 2006;24:2944&#x2013;2951. doi: 10.1016/j.vaccine.2005.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu C.H., Chu C., He C.C., Lin T.Y. Protection of Neonatal Mice from Lethal Enterovirus 71 Infection by Maternal Immunization with Attenuated Salmonella Enterica Serovar Typhimurium Expressing VP1 of Enterovirus 71. Microbes Infect. 2006;8:1671&#x2013;1678. doi: 10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G.W., Alonso S., Chow V.T.K., Poh C.L. Passive Protection against Lethal Enterovirus 71 Infection in Newborn Mice by Neutralizing Antibodies Elicited by a Synthetic Peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G.W., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T.K., Poh C.L. Identification of Neutralizing Linear Epitopes from the VP1 Capsid Protein of Enterovirus 71 Using Synthetic Peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusoff K., Tan W.S. Newcastle Disease Virus: Macromolecules and Opportunities. Avian Pathol. 2001:439&#x2013;455. doi: 10.1080/03079450120078626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03079450120078626</ArticleId><ArticleId IdType="pubmed">19184932</ArticleId></ArticleIdList></Reference><Reference><Citation>Errington W., Emmerson P.T. Assembly of Recombinant Newcastle Disease Virus Nucleocapsid Protein into Nucleocapsid like Structures Is Inhibited by the Phosphoprotein. J. Gen. Virol. 1997;78:2335&#x2013;2339. doi: 10.1099/0022-1317-78-9-2335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-9-2335</ArticleId><ArticleId IdType="pubmed">9292023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho C.L., Tan W.S., Yusoff K. Production of the Nucleocapsid Protein of Newcastle Disease Virus in Escherichia Coli and Its Assembly into Ring- and Nucleocapsid-like Particles. J. Microbiol. 2001;39:293&#x2013;299.</Citation></Reference><Reference><Citation>Rabu A., Tan W.S., Kho C.L., Omar A.R., Yusoff K. Chimeric Newcastle Disease Virus Nucleocapsid with Parts of Viral Hemagglutinin-Neuraminidase and Fusion Proteins. Acta Virol. 2002;46:211&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">12693857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho C.L., Tan W.S., Tey B.T., Yusoff K. Newcastle Disease Virus Nucleocapsid Protein: Self-Assembly and Length-Determination Domains. J. Gen. Virol. 2003:293&#x2013;299. doi: 10.1099/vir.0.19107-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19107-0</ArticleId><ArticleId IdType="pubmed">12867648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho C.L., Tan W.S., Tey B.T., Yusoff K. Regions on Nucleocapsid Protein of Newcastle Disease Virus That Interact with Its Phosphoprotein. Arch. Virol. 2004;149:997&#x2013;1005. doi: 10.1007/s00705-003-0273-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-003-0273-8</ArticleId><ArticleId IdType="pubmed">15098113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#x2019;ng W.C., Saw W.T., Yusoff K., Shafee N. Immunogenicity of a Truncated Enterovirus 71 VP1 Protein Fused to a Newcastle Disease Virus Nucleocapsid Protein Fragment in Mice. Acta Virol. 2011;55:227&#x2013;233. doi: 10.4149/av_2011_03_227.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2011_03_227</ArticleId><ArticleId IdType="pubmed">21978156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#x2019;ng W.C., Stanbridge E.J., Ong K.C., Wong K.T., Yusoff K., Shafee N. Partial Protection against Enterovirus 71 (EV71) Infection in a Mouse Model Immunized with Recombinant Newcastle Disease Virus Capsids Displaying the EV71 VP1 Fragment. J. Med. Virol. 2011;83:1783&#x2013;1791. doi: 10.1002/jmv.22198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.22198</ArticleId><ArticleId IdType="pubmed">21837796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasamugham L.A., Cardosa M.J., Tan W.S., Yusoff K. Recombinant Newcastle Disease Virus Capsids Displaying Enterovirus 71 VP1 Fragment Induce a Strong Immune Response in Rabbits. J. Med. Virol. 2006 doi: 10.1002/jmv.20668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20668</ArticleId><ArticleId IdType="pubmed">16789020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor; New York, NY, USA: 2001. pp. 132&#x2013;150.</Citation></Reference><Reference><Citation>Kyte J., Doolittle R.F. A Simple Method for Displaying the Hydropathic Character of a Protein. J. Mol. Biol. 1982;157:105&#x2013;132. doi: 10.1016/0022-2836(82)90515-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(82)90515-0</ArticleId><ArticleId IdType="pubmed">7108955</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader C., Schielke A., Ellerbroek L., Johne R. PCR Inhibitors&#x2014;Occurrence, Properties and Removal. J. Appl. Microbiol. 2012;113:1014&#x2013;1026. doi: 10.1111/j.1365-2672.2012.05384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2012.05384.x</ArticleId><ArticleId IdType="pubmed">22747964</ArticleId></ArticleIdList></Reference><Reference><Citation>Amann E., Ochs B., Abel K.J. Tightly Regulated Tac Promoter Vectors Useful for the Expression of Unfused and Fused Proteins in Escherichia Coli. Gene. 1988;69:301&#x2013;315. doi: 10.1016/0378-1119(88)90440-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(88)90440-4</ArticleId><ArticleId IdType="pubmed">3069586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengen P.N. Purification of His-Tag Fusion Proteins from Escherichia Coli. Trends Biochem. Sci. 1995;20:285&#x2013;286. doi: 10.1016/S0968-0004(00)89045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0004(00)89045-3</ArticleId><ArticleId IdType="pubmed">7667882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty D., Janin J., Robert C.H., Chakrabarti P. Changes in Protein Structure at the Interface Accompanying Complex Formation. IUCrJ. 2015;2:643&#x2013;652. doi: 10.1107/S2052252515015250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2052252515015250</ArticleId><ArticleId IdType="pmc">PMC4645109</ArticleId><ArticleId IdType="pubmed">26594372</ArticleId></ArticleIdList></Reference><Reference><Citation>Skeiky Y.A.W., Benson D.R., Elwasila M., Badaro R., Burns J.M., Reed S.G. Antigens Shared by Leishmania Species and Trypanosoma Cruzi: Immunological Comparison of the Acidic Ribosomal P0 Proteins. Infect. Immun. 1994;62:1643&#x2013;1651. doi: 10.1128/IAI.62.5.1643-1651.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.62.5.1643-1651.1994</ArticleId><ArticleId IdType="pmc">PMC186375</ArticleId><ArticleId IdType="pubmed">7513304</ArticleId></ArticleIdList></Reference><Reference><Citation>Potocnakova L., Bhide M., Pulzova L.B. An Introduction to B-Cell Epitope Mapping and in Silico Epitope Prediction. J. Immunol. Res. 2016;2016:6760830. doi: 10.1155/2016/6760830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6760830</ArticleId><ArticleId IdType="pmc">PMC5227168</ArticleId><ArticleId IdType="pubmed">28127568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler C., Neumaier P.S., Wolf W. Recognition Sequences of Restriction Endonucleases and Methylases&#x2014;A Review. Gene. 1985;33:1&#x2013;102. doi: 10.1016/0378-1119(85)90119-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(85)90119-2</ArticleId><ArticleId IdType="pubmed">2985469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia N.H., Joshua-Tor L. Strategies for Protein Coexpression in Escherichia Coli. Nat. Methods. 2006;3:55&#x2013;64. doi: 10.1038/nmeth0106-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0106-55</ArticleId><ArticleId IdType="pubmed">16369554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquet A., Daminet V., Haumont M., Garcia L., Chaudoir S., Bollen A., Biemans R. Expression of a Recombinant Toxoplasma Gondii ROP2 Fragment as a Fusion Protein in Bacteria Circumvents Insolubility and Proteolytic Degradation. Protein Expr. Purif. 1999;17:392&#x2013;400. doi: 10.1006/prep.1999.1150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/prep.1999.1150</ArticleId><ArticleId IdType="pubmed">10600457</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa S., Almeida A., Castro A., Domingues L. Fusion Tags for Protein Solubility, Purification, and Immunogenicity in Escherichia Coli: The Novel Fh8 System. Front. Microbiol. 2014;5:63. doi: 10.3389/fmicb.2014.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2014.00063</ArticleId><ArticleId IdType="pmc">PMC3928792</ArticleId><ArticleId IdType="pubmed">24600443</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco A., Ferrer-Miralles N., Garcia-Fruit&#xf3;s E., Mitraki A., Peternel S., Rinas U., Trujillo-Rold&#xe1;n M.A., Valdez-Cruz N.A., V&#xe1;zquez E., Villaverde A. Bacterial Inclusion Bodies Are Industrially Exploitable Amyloids&#x2014;PubMed. FEMS Microbiol. Rev. 2019;43:53&#x2013;72. doi: 10.1093/femsre/fuy038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsre/fuy038</ArticleId><ArticleId IdType="pubmed">30357330</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelberger J.R., Song W.C. Complement and Its Role in Innate and Adaptive Immune Responses. Cell Res. 2010;20:34&#x2013;50. doi: 10.1038/cr.2009.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2009.139</ArticleId><ArticleId IdType="pubmed">20010915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak W., Nied&#x17a;wiedzka-Rystwej P., Tokarz-Deptu&#x142;a B., Deptu&#x141;a W. Immunological Memory Cells. Cent. Eur. J. Immunol. 2018;43:194&#x2013;203. doi: 10.5114/ceji.2018.77390.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2018.77390</ArticleId><ArticleId IdType="pmc">PMC6102609</ArticleId><ArticleId IdType="pubmed">30135633</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Wang S., Gan W., Zhang W., Ju L., Huang Z., Lu S. Expression and Immunogenicity of Novel Subunit Enterovirus 71 VP1 Antigens. Biochem. Biophys. Res. Commun. 2012;420:755&#x2013;761. doi: 10.1016/j.bbrc.2012.03.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.03.067</ArticleId><ArticleId IdType="pubmed">22450314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Y., Wu C., Gu G., Sun W., Zhang Y.J., Zhou E.M. Improved Vaccine against PRRSV: Current Progress and Future Perspective. Front. Microbiol. 2017;8:1635. doi: 10.3389/fmicb.2017.01635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01635</ArticleId><ArticleId IdType="pmc">PMC5581347</ArticleId><ArticleId IdType="pubmed">28894443</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagioti E., Klenerman P., Lee L.N., van der Burg S.H., Arens R. Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. Front. Immunol. 2018;9:276. doi: 10.3389/fimmu.2018.00276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00276</ArticleId><ArticleId IdType="pmc">PMC5820320</ArticleId><ArticleId IdType="pubmed">29503649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng P.C., Lin C.N., Peng S.Y., Kang T.F., Lee K.M. Combined IL-12 Plasmid and Recombinant SjGST Enhance the Protective and Anti-Pathology Effect of SjGST DNA Vaccine Against Schistosoma Japonicum. PLoS Negl. Trop. Dis. 2016;10:e0004459. doi: 10.1371/journal.pntd.0004459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004459</ArticleId><ArticleId IdType="pmc">PMC4758724</ArticleId><ArticleId IdType="pubmed">26891172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>